Intriguingly, our targeted investigation indicates that tipifarnib treatment or silencing of the farnesylation substrate PTP4A1 in STK11-mutant lung cancer cells results in inhibition of proliferation as well as impaired tonic interferon signaling. Here, PTP4A1 is linked to lung cancer.